Cloverleaf Bio key facts
- Developer of a Ribonucleic Acid (RNA) therapeutics development platform designed to revolutionize cancer therapy and patient outcomes in oncology.
- It has raised $1.1M; the latest was Grant ($3.0M) in Jun 2025.
- Notable investors include Creative Destruction Lab, Endless Frontier Labs, Pillar VC, 2048 Ventures, Mission BioCapital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Cloverleaf Bio: the Monday email on marks, rounds and moves
Cloverleaf Bio funding rounds
No funding rounds for Cloverleaf Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cloverleaf Bio investors
10 investors are on record for Cloverleaf Bio, including Creative Destruction Lab, Endless Frontier Labs, Pillar VC and 2048 Ventures.
About Cloverleaf Bio
Developer of a Ribonucleic Acid (RNA) therapeutics development platform designed to revolutionize cancer therapy and patient outcomes in oncology. The company's platform allows for direct inhibition of various enzymes necessary for cancer growth from a single therapeutic molecule, enabling engineered tRNA therapeutics clinics to improve patient outcomes in oncology.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2023
- Employees
- 4
- Website
- cloverleafbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
Cloverleaf Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.